Oncogene - Table of Contents alert Volume 31 Issue 12

TABLE OF CONTENTS Volume 31, Issue 12 (March 2012) In this issue Review Original Articles Short Communications Also new AOP Advertisement $89 Trial Size Antibodies and Free Kindle! $89 trial size primary antibodies for cancer, cell biology, cell signaling and neuroscience research. All guaranteed to give predictable, repeatable results. Spend $900 and receive a free Kindle! Protect your experiments with Rockland antibodies. Compromise elsewhere. Click here to choose your $89 trial size antibodies or browse our content-rich website at www.rockland-inc.com Sign up for e-alerts Recommend to your library Web feed Subscribe Advertisement Take a look at this recent article published in Cancer Gene Therapy: Targeting 14-3-3zeta in cancer therapy FREE X Yang, W Cao, L Zhang, W Zhang, X Zhang and H Lin Cancer Gene Therapy doi:10.1038/cgt.2011.85   Review Top Cilia, adenomatous polyposis coli and associated diseases Z Li, W Li, L Song and W Zhu Oncogene 2012 31: 1475-1483; advance online publication, August 22, 2011; 10.1038/onc.2011.351 Abstract | Full Text Original Articles Top PP2A-B56α controls oncogene-induced senescence in normal and tumor human melanocytic cells S Mannava, A R Omilian, J A Wawrzyniak, E E Fink, D Zhuang, J C Miecznikowski, J R Marshall, M S Soengas, R C Sears, C D Morrison and M A Nikiforov Oncogene 2012 31: 1484-1492; advance online publication, August 8, 2011; 10.1038/onc.2011.339 Abstract | Full Text Fra-1 controls motility of bladder cancer cells via transcriptional upregulation of the receptor tyrosine kinase AXL A E Sayan, R Stanford, R Vickery, E Grigorenko, J Diesch, K Kulbicki, R Edwards, R Pal, P Greaves, I Jariel-Encontre, M Piechaczyk, M Kriajevska, J K Mellon, A S Dhillon and E Tulchinsky Oncogene 2012 31: 1493-1503; advance online publication, August 8, 2011; 10.1038/onc.2011.336 Abstract | Full Text Either Kras activation or Pten loss similarly enhance the dominant-stable CTNNB1-induced genetic program to promote granulosa cell tumor development in the ovary and testis J S Richards, H-Y Fan, Z Liu, M Tsoi, M-N Laguë, A Boyer and D Boerboom Oncogene 2012 31: 1504-1520; advance online publication, August 22, 2011; 10.1038/onc.2011.341 Abstract | Full Text MFG-E8/lactadherin regulates cyclins D1/D3 expression and enhances the tumorigenic potential of mammary epithelial cells C Carrascosa, R G Obula, E Missiaglia, H-A Lehr, M Delorenzi, M Frattini, C Rüegg and A Mariotti Oncogene 2012 31: 1521-1532; advance online publication, August 15, 2011; 10.1038/onc.2011.356 Abstract | Full Text Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia N Ånensen, S M Hjelle, W Van Belle, I Haaland, E Silden, J-C Bourdon, R Hovland, K Taskén, S Knappskog, P E Lønning, Ø Bruserud and B T Gjertsen Oncogene 2012 31: 1533-1545; advance online publication, August 22, 2011; 10.1038/onc.2011.348 Abstract | Full Text Deacetylation of FOXO3 by SIRT1 or SIRT2 leads to Skp2-mediated FOXO3 ubiquitination and degradation F Wang, C-H Chan, K Chen, X Guan, H-K Lin and Q Tong Oncogene 2012 31: 1546-1557; advance online publication, August 15, 2011; 10.1038/onc.2011.347 Abstract | Full Text A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth K L Streicher, W Zhu, K P Lehmann, R W Georgantas, C A Morehouse, P Brohawn, R A Carrasco, Z Xiao, D A Tice, B W Higgs, L Richman, B Jallal, K Ranade and Y Yao Oncogene 2012 31: 1558-1570; advance online publication, August 22, 2011; 10.1038/onc.2011.345 Abstract | Full Text Oncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastoma E E Santo, M E Ebus, J Koster, J H Schulte, A Lakeman, P van Sluis, J Vermeulen, D Gisselsson, I Øra, S Lindner, P G Buckley, R L Stallings, J Vandesompele, A Eggert, H N Caron, R Versteeg and J J Molenaar Oncogene 2012 31: 1571-1581; advance online publication, August 22, 2011; 10.1038/onc.2011.344 Abstract | Full Text Molecular chaperone complexes with antagonizing activities regulate stability and activity of the tumor suppressor LKB1 H Gaude, N Aznar, A Delay, A Bres, K Buchet-Poyau, C Caillat, A Vigouroux, C Rogon, A Woods, J-M Vanacker, J Höhfeld, C Perret, P Meyer, M Billaud and C Forcet Oncogene 2012 31: 1582-1591; advance online publication, August 22, 2011; 10.1038/onc.2011.342 Abstract | Full Text Short Communications Top A common single-nucleotide polymorphism in cyclooxygenase-2 disrupts microRNA-mediated regulation A E Moore, L E Young and D A Dixon Oncogene 2012 31: 1592-1598; advance online publication, August 8, 2011; 10.1038/onc.2011.349 Abstract | Full Text Cellular features of senescence during the evolution of human and murine ductal pancreatic cancer M E Caldwell, G M DeNicola, C P Martins, M A Jacobetz, A Maitra, R H Hruban and D A Tuveson Oncogene 2012 31: 1599-1608; advance online publication, August 22, 2011; 10.1038/onc.2011.350 Abstract | Full Text Advertisement Call for papers! Submit your best work in cancer research, including mechanisms of cellular oncogene activation, structure and function of encoded proteins, DNA and RNA tumor viruses and all other aspects of oncogene structure and function. Our online submission process is easy and can assist you in becoming part of this distinguished journal. Visit our Author page to learn about the benefits of publishing in the Journal and for guidelines on how to submit your paper.   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Oncogene. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.